As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted therapies for this patient population.
Professional organizations such as the National Comprehensive Cancer Network (NCCN) have adeptly remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.
In this lite paper, we take a critical look at lung cancer biomarker testing rates in the community practice setting and how they compare with NCCN guidelines utilizing data insights from the largest oncology testing database in the US.
Here, you’ll learn:
- How often lung cancer patients in the community setting are being tested for all nine actionable NCCN-recommended biomarkers
- The implications of current testing algorithms on time to treatment and tissue availability
- How real-world lab data provides evidence-based rationale for building precision oncology programs
To learn more about how real-world insights from NeoGenomics can support your precision oncology programs visit NeoEngage
Lite paper background: As a medical community, our understanding of the lung cancer universe has become increasingly sophisticated in recent years and as a result, significant advancements have been seen in targeted therapies for this patient population. Professional organizations such as the National Comprehensive Cancer Network (NCCN) have adeptly remained at the forefront of testing and treatment paradigms based on the latest available data and drug approvals. Guidelines from NCCN for non-small cell lung cancer (NSCLC) are among the most frequently updated, with seven revisions in 2021 alone. While this speaks to the speed of the evolving landscape, it can also create proverbial whiplash among providers of lung cancer patients as they navigate the multitude of testing and treating options available to them.
Co-authors:
Dr. Derek Lyle, Chief Medical Officer NeoGenomics Clinical Services
Kate Clark, Head of Client Engagement NeoGenomics Informatics